Our commitment to solutions: the ViiV Healthcare Global HIV and COVID-19 Emergency Response Fund
As the only company 100% dedicated to HIV, we have been actively exploring ways we can use our scientific, medical and community expertise to support the HIV community in addressing some of the specific challenges for people living with HIV during the COVID-19 pandemic. The £3 million ViiV Healthcare Global HIV and COVID-19 Emergency Response Fund will provide critical financial resources for research projects to study the medical and scientific impact COVID-19 is having on people living with HIV and community-based grants to help address specific challenges to the HIV community created by the pandemic.
To achieve this goal, the fund will be split into two parts:
The Research Emergency Response Fund will make available up to £1.5 million to be used for research grants for projects intended to help improve our understanding and management of the COVID-19 pandemic in people living with HIV. Allocated through a Request for Research Proposal (RFP) for Investigator Sponsored Studies (ISS) process, we will be seeking proposals that are focused on the impact of COVID-19 on people living with HIV. We believe this type of research is urgently needed. The application process for this grant will run from 27 April to 18 May 2020, and successful applicants will be notified by 5 June. For more information, including eligibility criteria and how to apply, please visit our Investigator Sponsored Studies (ISS) site via covid-19rfp.viivhealthcare.com or contact us via email on covid19rfp.research@viivhealthcare.com
The Community Emergency Response Fund will make available up to £1.5 million to support community-based organisations maintain and evolve their critical services for people living with/at risk of HIV during the COVID-19 crisis. The fund is available to existing grantees of Positive Action and/or Government Affairs and Global Public Health. Requests for proposals will be open from 27 April through to the 15 May. The proposals will be reviewed by an internal ViiV Healthcare panel and successful applicants notified by 25 May. For more information, including eligibility criteria and how to apply, please click on the appropriate link below:
Research and strong community systems are critical in the broader health response. Engaging local communities who are grounded in the response and working to support the healthcare system will save lives, and supporting research organisations will help us further understand the impact COVID-19 is having on people living with HIV.
We are proud to continue our mission of leaving no person with HIV behind.
For more information, see the ViiV Healthcare Global HIV and COVID-19 Emergency Response Fund Frequently Asked Questions.
For more updates on how we are continuing to contribute to the COVID-19 response, follow us on X
Media contacts
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries,email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
